InSilico Medicine Cayman TopCo (HKG:3696)

HKG:3696 Revenue

InSilico Medicine Cayman TopCo had revenue of $106.30M USD in the half year ending June 30, 2026, with 78.09% growth. This brings the company's total for the last twelve months to $135.09M, up 152.02% year-over-year. In the year 2025, InSilico Medicine Cayman TopCo had annual revenue of $56.24M, down -34.48%. That makes InSilico Medicine Cayman TopCo the 20,397th largest company in the world by revenue and 1,188th in Hong Kong.

• Revenue (ttm): $135.09M
• Revenue Growth: +152.02%
• P/S Ratio: 21.44
• Revenue / Employee: $405.66K
• Employees: 333
• Market Cap: 22.15B HKD

Revenue Chart

Chart

Chart

* This company reports financials in USD.

Revenue by Geography

Chart

• United States 31.57M 56.1%
• Chinese Mainland 17.53M 31.2%
• Kingdom of Saudi Arabia 1.82M 3.2%
• France 1.54M 2.7%
• Hong Kong 1.05M 1.9%
• Japan 620.00K 1.1%
• Others 618.00K 1.1%
• Other 1.49M 2.6%

Fiscal year ended Dec 31, 2025 See the full HKG:3696 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	56.24M	-29.60M	-34.48%
Dec 31, 2024	85.83M	34.65M	67.71%
Dec 31, 2023	51.18M	21.03M	69.77%
Dec 31, 2022	30.15M	-	-

Data Source: S&P Global Market Intelligence Last updated: Aug 26, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 17, 2026

Data Sources Report a data error